Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 98, Issue 2, 2005, Pages 217-221

  Miller, David Scott ^a   Blessing, John A ^b   Schilder, Jeanne ^c   Munkarah, Adnan ^d   Lee, Yi Chun ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c INDIANA UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Camptothecin; Carcinosarcoma; Topoisomerase 1 inhibition; Topotecan; Uterine neoplasms

Indexed keywords

BILIRUBIN; TOPOTECAN;

ADULT; AGED; ANAMNESIS; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BLOOD CLOTTING; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CARCINOSARCOMA; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; DYSPNEA; EDEMA; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPOKALEMIA; HYPOTENSION; HYPOTHERMIA; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; LUNG EDEMA; METABOLIC DISORDER; MIXED MULLERIAN TUMOR; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; UROGENITAL SYSTEM; UTERUS CARCINOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOSARCOMA; FEMALE; HUMANS; MIDDLE AGED; MIXED TUMOR, MULLERIAN; NEOPLASM RECURRENCE, LOCAL; TOPOTECAN; UTERINE NEOPLASMS;

EID: 22544451218     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.05.015     Document Type: Article

References (30)

1. J.T. Thigpen, J.A. Blessing, H.D. Homesley, N. Hacker, and S.L. Curry Phase II trial of piperazinedione in patients with advanced or recurrent uterine sarcoma. A Gynecologic Oncology Group study Am. J. Clin. Oncol. 8 1985 350 352
2. J.T. Thigpen, J.A. Blessing, J.W. Orr Jr., and P.J. DiSaia Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study Cancer Treat Rep. 70 1986 271 274
3. R.E. Slayton, J.A. Blessing, P.J. DiSaia, and W.A. Christopherson Phase II trial of etoposide in the management of advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group study Cancer Treat Rep. 71 1987 661 662
4. G.P. Sutton, J.A. Blessing, N. Rosenshein, G. Photopulos, and P.J. DiSaia Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study) Am. J. Obstet. Gynecol. 161 1989 309 312
5. H.B. Muss, B.N. Bundy, L. Adcock, and J. Beecham Mitoxantrone in the treatment of advanced uterine sarcoma. A phase II trial of the Gynecologic Oncology Group Am. J. Clin. Oncol. 13 1990 32 34
6. R.E. Slayton, J.A. Blessing, and D. Clarke-Pearson A phase II trial of diaziquone (AZQ) in mixed mesodermal sarcomas of the uterus. A Gynecologic Oncology Group study Invest. New Drugs 9 1991 93 94
7. J.T. Thigpen, J.A. Blessing, J. Beecham, H. Homesley, and E. Yordan Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study J. Clin. Oncol. 9 1991 1962 1966
8. J.M. Fowler, J.A. Blessing, R.A. Burger, and J.H. Malfetano Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study Gynecol. Oncol. 85 2002 311 314
9. J.P. Curtin, J.A. Blessing, J.T. Soper, and K. DeGeest Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study Gynecol. Oncol. 83 2001 268 270
10. R. Asbury, J.A. Blessing, E. Podczaski, and H. Ball A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study Am. J. Clin. Oncol. 21 1998 306 307
11. R. Asbury, J.A. Blessing, and D. Moore A phase II trail of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: a Gynecologic Oncology Group study Am. J. Clin. Oncol. 19 1996 400 402
12. G.P. Sutton, J.A. Blessing, H.D. Homesley, and J.H. Malfetano A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study Gynecol. Oncol. 53 1994 24 26
13. R.L. Coleman, and D.S. Miller Topotecan in the treatment of gynecologic cancer Semin. Oncol. 24 1997 S20-55 S20-63
14. P.J. Houghton, P.J. Cheshire, L. Myers, C.F. Stewart, T.W. Synold, and J.A. Houghton Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors Cancer Chemother. Pharmacol. 31 1992 229 239
15. D. Armstrong, and S. O'Reilly Clinical guidelines for managing topotecan related hematologic toxicity Oncologist 3 1998 4 10
16. J.A. Blessing Design, analysis, and interpretation of chemotherapy trials in gynecologic cancer G. Deppe Chemotherapy of gynecologic cancer 1990 Liss New York
17. S.G. Silverberg, F.J. Major, J.A. Blessing, B. Fetter, F.B. Askin, and S.Y. Liao Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases Int. J. Gynecol. Pathol. 9 1990 1 19
18. F.J. Major, J.A. Blessing, S.G. Silverberg, C.P. Morrow, W.T. Creasman, and J.L. Currie Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study Cancer 71 1993 1702 1709
19. G.A. Omura, J.A. Blessing, F. Major, S. Lifshitz, C.E. Ehrlich, and C. Mangan A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study J. Clin. Oncol. 3 1985 1240 1245
20. N.B. Hornback, G. Omura, and F.J. Major Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma Int. J. Radiat. Oncol. Biol. Phys. 12 1986 2127 2130
21. G.A. Omura, F.J. Major, J.A. Blessing, T.V. Sedlacek, J.T. Thigpen, and W.T. Creasman A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas Cancer 52 1983 626 632
22. H.B. Muss, B. Bundy, P.J. DiSaia, H.D. Homesley, W.C. Fowler Jr., and W. Creasman Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group) Cancer 55 1985 1648 1653
23. G. Sutton, V.L. Brunetto, L. Kilgore, J.T. Soper, R. McGehee, and G. Olt A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group study Gynecol. Oncol. 79 2000 147 153
24. D.S. Miller, J.A. Blessing, L.C. Kilgore, R. Mannel, and L. Van Le Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group study Am. J. Clin. Oncol. 23 2000 355 357
25. D.S. Miller, J.A. Blessing, S.S. Lentz, and S.E. Waggoner A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 87 2002 247 255
26. D.K. Armstrong Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity Oncologist 9 2004 33 42
27. M. Markman, J.A. Blessing, and K. De Geest Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial Gynecol. Oncol. 75 1999 444 446
28. M. Markman, J.A. Blessing, R.D. Alvarez, P. Hanjani, S. Waggoner, and K. Hall Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 77 2000 112 115
29. D.S. Miller, J.A. Blessing, S.S. Lentz, and D.S. McMeekin Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study Cancer 98 2003 1664 1669
30. S.M. Bhoola, R.L. Coleman, T. Herzog, R. Morris, C. Bryant, and J.M. Estes Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer Gynecol. Oncol. 95 3 2004 564 569